Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
It plans to deliver over 300 million doses to the Indian government
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
